Objective:To establish and optimize an autoverification system for thyroid function test reports of 5 items using historical test data.Methods:Based on the docoment' Autoverification of Clinical Laboratory Quantitative Test Results′, CLSI AUTO 10-A and AUTO 15 guidelines, an autoverification system for thyroid function test reports of 5 items was established combining with manual verification experience. A total of 193 860 thyroid function test reports of 5 items in 2021 were collected for the assessment of the original system. Totally 210 097 thyroid function test reports of 5 items in 2022 and 299 198 reports in 2023 were collected for the optimization of the autoverification system. There were 160 666 thyroid function test reports of 5 items from the first half of 2024 for the manual and autoverification comparison after optimization.Results:The pass rate of the autoverification system based on original thyroid function report in 2021 was 69.56%(134 849/193 860). The optimized system utilizing historical data from 2022 and 2023 covered 21 pattern rules and established verification for different patterns including range rules, delta check rules, and review rules. Taking manual verification as the standard for the data from the first half of 2024, the sensitivity and specificity of the optimized system were 100% (499/499) and 81.57% (130 646/160 167), respectively, with a false-negative rate of 0. The concordance rate between autoverification and manual verification was 81.63% (131 145/160 666), and the pass rate was 81.32% (130 646/160 666).Conclusion:Establishing and optimizing the autoverification system for thyroid function tests of 5 items using historical test data, and formulating verification rules for different patterns can be applied to clinical practise, which not only ensures the accuracy of test reports but also improves work efficiency, allowing continuously optimized and perfected of the system.

Objective:To investigate the therapeutic effect of Brucea javanica oil emulsion combined with chemotherapy for advanced lung squamous cell carcinoma.Methods:A retrospective cohort study was conducted. The clinical data from 120 patients with lung squamous cell carcinoma at stage Ⅳ in Shanxi Province Cancer Hospital between January 2019 and December 2020 were retrospectively analyzed. According to the treatment regimens, all patients were divided into Brucea javanica oil emulsion combined with chemotherapy group (the observation group, 60 cases) and chemotherapy alone group (the control group, 60 cases). Immune function, efficacy, and chemotherapy-related adverse effects were compared between the 2 groups before and after treatment.Results:Among 120 patients, there were 77 males and 43 females, with the age of (67±7) years. There were no statistically differences in basic information between the 2 groups (all P > 0.05). The proportion of CD4 + cells and the ratio of CD4 + to CD8 + in the observation group after treatment increased compared to those before treatment, while the proportion of CD8 + decreased (all P < 0.001). In the control group, the proportions of CD3 +, CD4 +, NK cells decreased after treatment (all P < 0.001). There were no statistically significant differences in the T cell subsets between the 2 groups before treatment (all P > 0.05); after treatment, the proportions of CD3 +, CD4 +, NK cells and the ratio of CD4 + to CD8 + in the observation group were all higher than those in the control group, and the proportion of CD8 + cells was lower than that in the control group (all P < 0.001). The disease control rate (DCR) in the observation group was higher than that in the control group [73.3% (44/60) vs. 55.0% (33/60)], and the difference was statistically significant ( χ2 = 4.39, P = 0.036). The median progression-free survivals (PFS) time was 7.833 months (95% CI: 6.927-8.739 months), 5.433 months (95% CI: 3.878-6.988 months), and the difference was statistically significant ( χ2 = 4.84, P = 0.028). The incidence of leukopenia was 38.3% (23/60), 60.0% (36/60), respectively in the observation group and the control group ( χ2 = 5.64, P = 0.018); the incidence of thrombocytopenia was 21.7% (13/60), 38.3% (23/60), respectively in the observation group and the control group ( χ2 = 3.97, P = 0.046). Conclusions:Brucea javanica oil emulsion combined with chemotherapy can improve immune function, increase DCR, and reduce myelosuppression of patients with advanced lung squamous cell carcinoma.

Purpose To investigate the clinicopathological features,differential diagnosis and prognosis of atypical fibroxanthoma(AFX).Methods Pathological features of 15 cases of AFX and 3 cases of pleomorphic dermal sarcoma(PDS)misdiagnosed as AFX were retrospectively analyzed by hematoxylin and eosin staining and immunohistochemical EnVision staining technology.Clinical information was collected and analyzed,and the relevant literatures were re-viewed.Results The age of the 15 patients with AFX ranged from 18 to 78 years,with an average age of 57 years.4 cases occurred in the head and neck,and 11 cases occurred in the trunk and limbs.3 patients with PDS misdiagnosed as AFX were aged from 56 to 60 years,with an average age of 58 years.The tumors were located in the trunk and limbs.Microscopically,15 cases of AFX and 3 cases of PDS misdiagnosed as AFX were composed of proliferative pleo-morphic and atypical spindle cells interspersed with a varying number of multinucleated cells.15 cases of AFX tumors were superficial and located in the dermis.In 3 cases of PDS misdiagnosed as AFX,1 case was located in subcutane-ous adipose tissue,1 case had superficial subcutaneous extension,and the third case had positive basal margin.Immu-nohistochemically,the immunophenotypes of the two groups were consistent.CD10 was expressed in all cases,CD68 was positive in most cases,SMA was expressed in a few cases,desmin was focal expressed in a very few cases,and S-100,SOX10,CD34,HMB-45,Melan A,STAT6 and CK(AE1/AE3)were not expressed in all cases.Ki67 prolifera-tion index ranged from 2％to 30％.15 patients with AFX were followed up from 12 to 108 months.One patient had tumor recurrence 1 year and 3 years after operation due to positive basal margin.Most of the other patients underwent extended resection after diagnosis and were in good condition without tumor recurrence and metastasis.3 cases of PDS misdiagnosed as AFX were followed up for 31 to 78 months.One patient had lung metastasis after 2 years,one patient recurred 4 times after operation,and the other patient died after 4 times of recurrence.Conclusion AFX is a rare dis-ease with similar pathological characteristics and immunophenotype to PDS.AFX can be diagnosed only when the tumor is small and completely confined to the dermis.When the maximum diameter of the tumor is more than 3 cm,or the presence of any form of subcutaneous extension requires a high level of vigilance for PDS.Careful differentiation and correct classification of AFX and PDS are very important for the treatment and prognosis of the disease.

Purpose To investigate the clinicopathological features,differential diagnosis and prognosis of atypical fibroxanthoma(AFX).Methods Pathological features of 15 cases of AFX and 3 cases of pleomorphic dermal sarcoma(PDS)misdiagnosed as AFX were retrospectively analyzed by hematoxylin and eosin staining and immunohistochemical EnVision staining technology.Clinical information was collected and analyzed,and the relevant literatures were re-viewed.Results The age of the 15 patients with AFX ranged from 18 to 78 years,with an average age of 57 years.4 cases occurred in the head and neck,and 11 cases occurred in the trunk and limbs.3 patients with PDS misdiagnosed as AFX were aged from 56 to 60 years,with an average age of 58 years.The tumors were located in the trunk and limbs.Microscopically,15 cases of AFX and 3 cases of PDS misdiagnosed as AFX were composed of proliferative pleo-morphic and atypical spindle cells interspersed with a varying number of multinucleated cells.15 cases of AFX tumors were superficial and located in the dermis.In 3 cases of PDS misdiagnosed as AFX,1 case was located in subcutane-ous adipose tissue,1 case had superficial subcutaneous extension,and the third case had positive basal margin.Immu-nohistochemically,the immunophenotypes of the two groups were consistent.CD10 was expressed in all cases,CD68 was positive in most cases,SMA was expressed in a few cases,desmin was focal expressed in a very few cases,and S-100,SOX10,CD34,HMB-45,Melan A,STAT6 and CK(AE1/AE3)were not expressed in all cases.Ki67 prolifera-tion index ranged from 2％to 30％.15 patients with AFX were followed up from 12 to 108 months.One patient had tumor recurrence 1 year and 3 years after operation due to positive basal margin.Most of the other patients underwent extended resection after diagnosis and were in good condition without tumor recurrence and metastasis.3 cases of PDS misdiagnosed as AFX were followed up for 31 to 78 months.One patient had lung metastasis after 2 years,one patient recurred 4 times after operation,and the other patient died after 4 times of recurrence.Conclusion AFX is a rare dis-ease with similar pathological characteristics and immunophenotype to PDS.AFX can be diagnosed only when the tumor is small and completely confined to the dermis.When the maximum diameter of the tumor is more than 3 cm,or the presence of any form of subcutaneous extension requires a high level of vigilance for PDS.Careful differentiation and correct classification of AFX and PDS are very important for the treatment and prognosis of the disease.

Objective:To establish and optimize an autoverification system for thyroid function test reports of 5 items using historical test data.Methods:Based on the docoment' Autoverification of Clinical Laboratory Quantitative Test Results′, CLSI AUTO 10-A and AUTO 15 guidelines, an autoverification system for thyroid function test reports of 5 items was established combining with manual verification experience. A total of 193 860 thyroid function test reports of 5 items in 2021 were collected for the assessment of the original system. Totally 210 097 thyroid function test reports of 5 items in 2022 and 299 198 reports in 2023 were collected for the optimization of the autoverification system. There were 160 666 thyroid function test reports of 5 items from the first half of 2024 for the manual and autoverification comparison after optimization.Results:The pass rate of the autoverification system based on original thyroid function report in 2021 was 69.56%(134 849/193 860). The optimized system utilizing historical data from 2022 and 2023 covered 21 pattern rules and established verification for different patterns including range rules, delta check rules, and review rules. Taking manual verification as the standard for the data from the first half of 2024, the sensitivity and specificity of the optimized system were 100% (499/499) and 81.57% (130 646/160 167), respectively, with a false-negative rate of 0. The concordance rate between autoverification and manual verification was 81.63% (131 145/160 666), and the pass rate was 81.32% (130 646/160 666).Conclusion:Establishing and optimizing the autoverification system for thyroid function tests of 5 items using historical test data, and formulating verification rules for different patterns can be applied to clinical practise, which not only ensures the accuracy of test reports but also improves work efficiency, allowing continuously optimized and perfected of the system.

Objective:To investigate the therapeutic effect of Brucea javanica oil emulsion combined with chemotherapy for advanced lung squamous cell carcinoma.Methods:A retrospective cohort study was conducted. The clinical data from 120 patients with lung squamous cell carcinoma at stage Ⅳ in Shanxi Province Cancer Hospital between January 2019 and December 2020 were retrospectively analyzed. According to the treatment regimens, all patients were divided into Brucea javanica oil emulsion combined with chemotherapy group (the observation group, 60 cases) and chemotherapy alone group (the control group, 60 cases). Immune function, efficacy, and chemotherapy-related adverse effects were compared between the 2 groups before and after treatment.Results:Among 120 patients, there were 77 males and 43 females, with the age of (67±7) years. There were no statistically differences in basic information between the 2 groups (all P > 0.05). The proportion of CD4 + cells and the ratio of CD4 + to CD8 + in the observation group after treatment increased compared to those before treatment, while the proportion of CD8 + decreased (all P < 0.001). In the control group, the proportions of CD3 +, CD4 +, NK cells decreased after treatment (all P < 0.001). There were no statistically significant differences in the T cell subsets between the 2 groups before treatment (all P > 0.05); after treatment, the proportions of CD3 +, CD4 +, NK cells and the ratio of CD4 + to CD8 + in the observation group were all higher than those in the control group, and the proportion of CD8 + cells was lower than that in the control group (all P < 0.001). The disease control rate (DCR) in the observation group was higher than that in the control group [73.3% (44/60) vs. 55.0% (33/60)], and the difference was statistically significant ( χ2 = 4.39, P = 0.036). The median progression-free survivals (PFS) time was 7.833 months (95% CI: 6.927-8.739 months), 5.433 months (95% CI: 3.878-6.988 months), and the difference was statistically significant ( χ2 = 4.84, P = 0.028). The incidence of leukopenia was 38.3% (23/60), 60.0% (36/60), respectively in the observation group and the control group ( χ2 = 5.64, P = 0.018); the incidence of thrombocytopenia was 21.7% (13/60), 38.3% (23/60), respectively in the observation group and the control group ( χ2 = 3.97, P = 0.046). Conclusions:Brucea javanica oil emulsion combined with chemotherapy can improve immune function, increase DCR, and reduce myelosuppression of patients with advanced lung squamous cell carcinoma.

Objective:To explore the effect of smoking on the sleep quality of military pilots.Methods:A questionnaire survey was conducted among military pilots who underwent a modified physical examination in Air Force Medical Center. The pilots were divided into smoking group and non-smoking group according to whether they smoked or not, and the Pittsburgh Sleep Quality Index (PSQI) was used to assess their sleep quality. The difference in sleep quality was compared between 2 groups.Results:A total of 665 questionnaires were issued, of which 627 were valid, with an effective rate of 94.29%. There were 291 pilots in smoking group and 336 in non-smoking group. The average sleep time of 627 military pilots was (7.58±0.70) h, and the average PSQI score was (2.93±0.09) points. The PSQI score of the smoking group was (3.28±0.14) points, and the PSQI score of the non-smoking group was (2.63±0.10) points, and the difference between 2 groups was significant ( Z=-3.17, P=0.002). Among the factors of the PSQI scale, there were significant differences in sleep onset time, sleep time, sleep efficiency, sleep disorder and daytime dysfunction between the smoking group and the non-smoking group ( Z=-5.85, -2.47, -1.98, -2.18, -1.98, P<0.001,=0.014, 0.049, 0.029, 0.049), and there was no statistically significance in sleep quality and hypnotic drugs intake ( Z=-1.65, -0.94, P=0.098, 0.347). Conclusions:Smoking can affect the sleep quality of military pilots, and it is necessary to actively carry out propaganda and education to persuade pilots away from smoking and maintain physical health.

Objective:To explore the effect of smoking on the sleep quality of military pilots.Methods:A questionnaire survey was conducted among military pilots who underwent a modified physical examination in Air Force Medical Center. The pilots were divided into smoking group and non-smoking group according to whether they smoked or not, and the Pittsburgh Sleep Quality Index (PSQI) was used to assess their sleep quality. The difference in sleep quality was compared between 2 groups.Results:A total of 665 questionnaires were issued, of which 627 were valid, with an effective rate of 94.29%. There were 291 pilots in smoking group and 336 in non-smoking group. The average sleep time of 627 military pilots was (7.58±0.70) h, and the average PSQI score was (2.93±0.09) points. The PSQI score of the smoking group was (3.28±0.14) points, and the PSQI score of the non-smoking group was (2.63±0.10) points, and the difference between 2 groups was significant ( Z=-3.17, P=0.002). Among the factors of the PSQI scale, there were significant differences in sleep onset time, sleep time, sleep efficiency, sleep disorder and daytime dysfunction between the smoking group and the non-smoking group ( Z=-5.85, -2.47, -1.98, -2.18, -1.98, P<0.001,=0.014, 0.049, 0.029, 0.049), and there was no statistically significance in sleep quality and hypnotic drugs intake ( Z=-1.65, -0.94, P=0.098, 0.347). Conclusions:Smoking can affect the sleep quality of military pilots, and it is necessary to actively carry out propaganda and education to persuade pilots away from smoking and maintain physical health.

Abstract On April 25, 2021, a case with hookworm infections was identified during the surveillance of soil-borne nematodiasis by Tiantai Center for Disease Control and Prevention, Taizhou City, Zhejiang Province. The patients was admitted to a county people's hospital due to dizziness and limb weakness on July 24, 2020. Laboratory tests showed 2.5×1012/L red blood cell counts, 45 g/L hemoglobin, 3.4% eosinophil percentage, 4.7 μmol/L serum iron and <1 μg/L ferritin, and severe iron-deficiency anemia was initially diagnosed. Following treatment with blood transfusion and ion supplement, subsequent three routine blood tests indicated elevated eosinophil percentages. On April 25, 2021, hookworm eggs were detected in stool samples using Kate-Katz technique, and Necator americanus was identified with the test-tube filter-paper culture method. Severe iron-deficiency anemia caused by hookworm infections was diagnosed based on field epidemiological surveys and laboratory tests. The health education pertaining to parasitic disease control knowledge among residents and the diagnosis and treatment of parasitic diseases in medical institutions are recommended to be improved in rural areas to avoid misdiagnosis and missing diagnosis.

COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread across the globe, posing an enormous threat to public health and safety. Traditional Chinese medicine (TCM), in combination with Western medicine (WM), has made important and lasting contributions in the battle against COVID-19. In this review, updated clinical effects and potential mechanisms of TCM, presented in newly recognized three distinct phases of the disease, are summarized and discussed. By integrating the available clinical and preclinical evidence, the efficacies and underlying mechanisms of TCM on COVID-19, including the highly recommended three Chinese patent medicines and three Chinese medicine formulas, are described in a panorama. We hope that this comprehensive review not only provides a reference for health care professionals and the public to recognize the significant contributions of TCM for COVID-19, but also serves as an evidence-based in-depth summary and analysis to facilitate understanding the true scientific value of TCM.